spiron (spironolactone orion) tafla 100 mg
orion corporation - spironolactonum inn - tafla - 100 mg
spiron (spironolactone orion) tafla 25 mg
orion corporation - spironolactonum inn - tafla - 25 mg
spiron (spironolactone orion) tafla 50 mg
orion corporation - spironolactonum inn - tafla - 50 mg
xtandi
astellas pharma europe b.v. - enzalutamíð - blöðruhálskirtli - innkirtla meðferð - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.
erleada
janssen-cilag international nv - apalutamide - blöðruhálskirtli - innkirtla meðferð - erleada er ætlað:í fullorðnir menn í meðferð ekki sjúklingum gelding þola krabbamein í blöðruhálskirtli (nmcrpc) sem eru á mikil hætta á að fá sjúklingum sjúkdómur. í fullorðnir menn fyrir meðferð af sjúklingum hormón-viðkvæm krabbamein í blöðruhálskirtli (mhspc) ásamt andrógen skort meðferð (adt).
xofigo
bayer ag - radium (223ra) dichloride - blöðruhálskirtli - heilsueyðandi lyf - xofigo er ætlað til meðferðar hjá fullorðnum með krabbameinsvaldandi blöðruhálskirtilskrabbameini, meinvörpum í beinum og engin þekkt meinvörp í meltingarvegi.
qaialdo
nova laboratories ireland limited - spironolactone - edema; heart failure; liver cirrhosis; ascites; nephrotic syndrome; hyperaldosteronism; essential hypertension - antihypertensives and diuretics in combination - in the management of refractory oedema associated with congestive cardiac failure; hepatic cirrhosis with ascites and oedema, malignant ascites, nephrotic syndrome, diagnosis and treatment of primary aldosteronism, essential hypertension. neonates, children and adolescents should only be treated under guidance of a paediatric specialist (see sections 5. 1 5.